The effect of theobromine supplementation on anthropometric indices, glycemic indices, cardiovascular risk factors, and genes expression of PPARa and Sirt1 in subjects with metabolic syndrome.

Iran University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•Overweight or obese (25 =BMI= 35 kg/m^2) men and women aged 40 to 55 years .
•Having metabolic syndrome according to IDF definition ( Waist circumference greater than 94 cm for men and 80 cm for women, Triglyceride = 150mg/dl, HDL-c = 40mg/dl for men and HDL-c = 50mg/dl for women or medication, Systolic blood pressure = 130mmHg and DBP= 85 mmHg or medication, Fasting blood sugar= 100mg/dl or medication)
•Tendency to participate in the study

•Subjects with diabetes, cancer, hepatitis, cardiovascular diseases, hematological disorders, Neurological disorders, renal disorders, gastrointestinal and thyroid disorders
•Insulin therapy, use hypoglycemic and weight reduction medication, vasodilators, hormone therapy, corticosteroids, non steroid anti inflammatory drugs, antihistamines, Selective serotonin reuptake inhibitors, anti gout and psychotics medication.
•Use of any vitamin and mineral supplement, antioxidants and omega3.
•Pregnancy, lactation and adherence to a specific diet
•People treated with statins and antihypertensive drugs will only be included in the study if they are treated for more than 3 months for statins and more than 6 months for high blood pressure.

发起方